| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/J.SEMINONCOL.2012.05.014 |
| P698 | PubMed publication ID | 22846866 |
| P2093 | author name string | Andrew X. Zhu | |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 493-502 | |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | Seminars in Oncology | Q14330412 |
| P1476 | title | Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives | |
| P478 | volume | 39 |
| Q36223538 | A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib |
| Q41910456 | AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-κB signaling pathway in hepatocellular carcinoma. |
| Q38792676 | AMPK and PKA interaction in the regulation of survival of liver cancer cells subjected to glucose starvation. |
| Q31119684 | Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma |
| Q47094775 | Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study |
| Q36693594 | Comparison of laparoscopic hepatectomy, percutaneous radiofrequency ablation and open hepatectomy in the treatment of small hepatocellular carcinoma. |
| Q53088926 | Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma |
| Q26996359 | Complications after percutaneous ablation of liver tumors: a systematic review |
| Q40729549 | Current chemotherapies for advanced hepatocellular carcinoma |
| Q50941733 | Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma |
| Q47365566 | Diagnostic significance and potential function of miR-338-5p in hepatocellular carcinoma: A bioinformatics study with microarray and RNA sequencing data |
| Q39063025 | Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma |
| Q36309446 | Genetic polymorphisms in apoptosis-related genes and the prognosis of hepatocellular carcinoma |
| Q36299617 | Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development |
| Q41637262 | Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model. |
| Q38584060 | Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. |
| Q37315447 | Identification of driver genes in hepatocellular carcinoma by exome sequencing |
| Q36075407 | Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer |
| Q34253205 | Increased level of nucleolin confers to aggressive tumor progression and poor prognosis in patients with hepatocellular carcinoma after hepatectomy |
| Q54325319 | Inhibition of mammalian target of rapamycin aggravates the respiratory burst defect of neutrophils from decompensated patients with cirrhosis |
| Q54111915 | Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. |
| Q35913384 | Liver cancer oncogenomics: opportunities and dilemmas for clinical applications |
| Q58548120 | Lymphoid Enhancer Factor 1 Contributes to Hepatocellular Carcinoma Progression Through Transcriptional Regulation of Epithelial-Mesenchymal Transition Regulators and Stemness Genes |
| Q40948560 | MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma |
| Q47098482 | MicroRNA-30a-5p suppresses proliferation, invasion and tumor growth of hepatocellular cancer cells via targeting FOXA1. |
| Q38724154 | MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression |
| Q42105768 | Mutually exclusive acetylation and ubiquitylation among enzymes involved in glucose metabolism |
| Q35100996 | New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing |
| Q53685286 | PDXliver: a database of liver cancer patient derived xenograft mouse models |
| Q34995167 | Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways |
| Q39420444 | Preparation of Microspheres Encapsulating a Recombinant TIMP-1 Adenovirus and their Inhibition of Proliferation of Hepatocellular Carcinoma Cells |
| Q42181737 | Prognostic value of combined aquaporin 3 and aquaporin 5 overexpression in hepatocellular carcinoma |
| Q36625697 | Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma |
| Q37722129 | TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma |
| Q89939081 | Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles |
| Q64886353 | Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib. |
| Q47121517 | The 4th Asia-Pacific Primary Liver Cancer Expert Meeting |
| Q46258349 | The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): A Bridge to a Consensus on HCC Management, Taipei, Taiwan, July 11-13, 2014. |
| Q38062681 | Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. |
| Q37255838 | Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations |
| Q38721192 | Upregulation of PREX2 promotes the proliferation and migration of hepatocellular carcinoma cells via PTEN-AKT signaling |
| Q37708976 | Vitexin suppresses autophagy to induce apoptosis in hepatocellular carcinoma via activation of the JNK signaling pathway |
| Q40985945 | miR-492G>C polymorphism (rs2289030) is associated with overall survival of hepatocellular carcinoma patients |
Search more.